Cover Image
市場調查報告書

復發性多發性硬化症(RMS):開發中產品分析

Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 269901
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
復發性多發性硬化症(RMS):開發中產品分析 Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015
出版日期: 2015年11月30日 內容資訊: 英文 70 Pages
簡介

復發性多發性硬化症(RMS)起因於中樞神經系統發炎造成的脫髓鞘疾病。脫髓鞘會延緩神經訊號的傳達,而誘發多發性硬化症的症狀。症狀包含肌肉無力,視覺障礙,平衡障礙,腸或膀胱控制的喪失。

本報告提供復發性多發性硬化症(RMS)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

  • 調查範圍

復發性多發性硬化症(RMS)概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

復發性多發性硬化症(RMS):企業開發中的治療藥

復發性多發性硬化症(RMS):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

復發性多發性硬化症(RMS):企業開發中的產品

復發性多發性硬化症(RMS)的治療藥開發作的企業

  • BIOCAD
  • Cognosci, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Mallinckrodt plc
  • Receptos, Inc.
  • Teva Pharmaceutical Industries Limited

復發性多發性硬化症(RMS):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • COG-133
  • corticotropin
  • DC-TAB
  • glatiramer acetate
  • GZ-402668
  • interferon beta-1a
  • ocrelizumab
  • ozanimod
  • peginterferon beta 1a

復發性多發性硬化症(RMS):開發平台的更新

復發性多發性硬化症(RMS):暫停中的計劃

復發性多發性硬化症(RMS):中止的產品

復發性多發性硬化症(RMS):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7370IDB

Summary

Global Markets Direct's, 'Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2015', provides an overview of the Relapsing Multiple Sclerosis (RMS)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Relapsing Multiple Sclerosis (RMS)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Relapsing Multiple Sclerosis (RMS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Relapsing Multiple Sclerosis (RMS) Overview
  • Therapeutics Development
    • Pipeline Products for Relapsing Multiple Sclerosis (RMS) - Overview
  • Relapsing Multiple Sclerosis (RMS) - Therapeutics under Development by Companies
  • Relapsing Multiple Sclerosis (RMS) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Relapsing Multiple Sclerosis (RMS) - Products under Development by Companies
  • Relapsing Multiple Sclerosis (RMS) - Companies Involved in Therapeutics Development
    • AbbVie Inc.
    • Actelion Ltd
    • BIOCAD
    • Cognosci, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Genzyme Corporation
    • Merck KGaA
    • Pfenex Inc.
    • Receptos, Inc.
    • VivaCell Biotechnology Espana S.L.
  • Relapsing Multiple Sclerosis (RMS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles ABT-555 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cladribine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COG-133 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DC-TAB - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GZ-402668 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon beta-1a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon beta-1b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ocrelizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ozanimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • peginterferon beta 1a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-726 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ponesimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCE-0032 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Relapsing Multiple Sclerosis (RMS) - Recent Pipeline Updates
  • Relapsing Multiple Sclerosis (RMS) - Dormant Projects
  • Relapsing Multiple Sclerosis (RMS) - Discontinued Products
  • Relapsing Multiple Sclerosis (RMS) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 08, 2015: Roche's ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis
      • Dec 22, 2014: Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
      • Jun 09, 2014: Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
      • Jan 06, 2014: Receptos Begins Enrollment of Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
      • Jun 05, 2013: Receptos Provides Update On Progress Of Lead Product Candidate RPC1063
      • Jan 17, 2012: Genentech Recruits Investigators For Two Phase III Studies Comparing Ocrelizumab To Rebif In People With Relapsing Multiple Sclerosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by AbbVie Inc., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Actelion Ltd, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by BIOCAD, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Cognosci, Inc., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Genzyme Corporation, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Merck KGaA, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Pfenex Inc., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by Receptos, Inc., H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Relapsing Multiple Sclerosis (RMS) Therapeutics - Recent Pipeline Updates, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Dormant Projects, H2 2015
  • Relapsing Multiple Sclerosis (RMS) - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Relapsing Multiple Sclerosis (RMS), H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top